Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilcock, Gordon K., Gauthier, Serge, Frisoni, Giovanni B., Jia, Jianping, Hardlund, Jiri H., Moebius, Hans J., Bentham, Peter, Kook, Karin A., Schelter, Bjoern O., Wischik, Damon J., Davis, Charles S., Staff, Roger T., Vuksanovic, Vesna, Ahearn, Trevor, Bracoud, Luc, Shamsi, Kohkan, Marek, Ken, Seibyl, John, Riedel, Gernot, Storey, John M.D., Harrington, Charles R., Wischik, Claude M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734125/
https://www.ncbi.nlm.nih.gov/pubmed/29154277
http://dx.doi.org/10.3233/JAD-170560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734125/
https://www.ncbi.nlm.nih.gov/pubmed/29154277
http://dx.doi.org/10.3233/JAD-170560

Ejemplares similares